Iridex (IRIX) Net Equity Issued and Repurchased (2017 - 2022)

Iridex's (IRIX) quarterly Net Equity Issued and Repurchased came in at -$9.9 million in Q4 2022, down 200.0% quarter-over-quarter from $9.9 million in Q2 2021.

Iridex (IRIX) Net Equity Issued and Repurchased (2017 - 2022) Analysis & Trends

Iridex's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at -$9.9 million for Q4 2022.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$9.9 million in Q4 2022; TTM through Sep 2025 was -$9.9 million, a 0.0% change from a year earlier, with the FY2026 full-year figure at $6.0 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased eased to -$9.9 million in Q4 2022 per IRIX's latest filing, from $9.9 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $9.9 million in Q2 2021 and bottomed at -$9.9 million in Q4 2022.
  • The 3-year median for Net Equity Issued and Repurchased is -$162000.0 (2018), against an average of -$54000.0.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Iridex 15.93 Mn 11.33 Mn 4.74 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 -9.88 Mn
Dec 31, 2022 -9.88 Mn
Apr 3, 2021 9.88 Mn
Apr 3, 2021 9.88 Mn
Dec 29, 2018 -162,000.00
Dec 29, 2018 -162,000.00
Apr 1, 2017 2.26 Mn
Apr 1, 2017 2.26 Mn